Pharmafile Logo

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

- PMLiVE

As we move forward in 2024, the healthcare industry has embraced the idea that AI-generated synthetic patients are here for the long haul. The remarkable ability to utilize artificial patients that mimic real-world patient data addresses crucial unmet needs, making it nearly impossible to envision a future healthcare industry without widespread usage and integration of synthetic patients.

However, we must strike a delicate balance between integrating AI tools into market research and acknowledging the invaluable role of human intelligence in understanding, verifying, supervising and analysing insights. In this article, we delve into the compelling arguments surrounding the opportunities and risks associated with the utilization of AI-generated synthetic patients in healthcare market research.

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize...

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the...

Precision Medical Affairs in Action: Using AI and Analytics to Elevate Strategy, Engagement, and Impact

Discover how AI, analytics and real-world data are reshaping Medical Affairs.

How did multifaceted support from across Inizio help a biotech firm prepare for launch?

Discover how teams from across Inizio provided a range of integrated services to give a client's product the best chance of launch success.

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

Explore Inizio Medical's key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.

Intelligent field team engagement: Turning shared knowledge into deeper insights and better decisions.

At Age of AI 2026, Inizio Medical’s Phil Wakefield and Inizio Ignite’s Tim Luxford will explore how cross-functional collaboration and AI can unlock faster, more actionable insights across medical and...

AI in practice: 4 real-world use cases in health and life sciences

Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it...

How will AI change field training?

Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...

Inizio Ignite Sparks a New Era of Connected Advisory Solutions

Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.